Aprea Therapeutics Announces One-for-Twenty Reverse Stock Split
DOYLESTOWN, Pa., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (the “Company”), a biopharmaceutical company focused on developing...
Coronavirus
HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers
NEW YORK and VIENNA, Austria, Feb. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing...
Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Fully Human and Murine Anti-SARS-CoV-2 Monoclonal Antibodies
Immunocompromised Individuals, Including Organ Transplant Recipients, Are at Increased Risk of Severe COVID-19 and Poor Clinical Outcomes SARS-CoV-2 has Mutated...
Clinical Trials – Outlook And Trends For 2023
Clinical trials for testing potential drugs, procedures, or devices have evolved over hundreds of years. Scientists use clinical trials on...
Bioxytran Receives Approval to Initiate Trials with ProLectin-I
BOSTON, MASSACHUSETTS, Feb. 06, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing...
LumiraDx Receives FDA Emergency Use Authorization and UK CTDA Approval for its Fast Lab Solutions Multiplex COVID and Influenza Molecular Assay
LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete assay receives Emergency Use Authorization from the FDA along with being successfully...
Arbutus to Participate in Three Upcoming Investor Conferences
WARMINSTER, Pa., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive...
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Record and Meeting Dates for its first Annual Meeting of Stockholders
PALO ALTO, Calif., Feb. 04, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento...
Sorrento Distributes Dividend Confirmation Statements to 146 Brokerage Firms and Provides Specific Instruction to Continental Stock Transfer & Trust Company Regarding the Dividend of Scilex Holding Company Common Stock
SAN DIEGO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today distributed dividend confirmation statements to...
Invivyd Announces Changes to Executive Team
WALTHAM, Mass., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical stage biopharmaceutical company on a mission...
Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant Cancers
Development expected to capitalize upon tumor targeting Quatramers™ MUC1-C could be effective against a number of drug resistant cancers such...
Junshi Biosciences Announces Approval for Marketing of VV116 in China
SHANGHAI, China, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a...
Aprea Therapeutics Appoints John Hamill as Chief Financial Officer
DOYLESTOWN, Pa., Jan. 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic...
Cocrystal Pharma Announces Participation in Virtual Investor Events
BOTHELL, Wash., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) announces the participation of James Martin, co-CEO...
Roche launches COVID-19 PCR test to detect the fast spreading XBB.1.5 Omicron sub-variant
This new test for researchers specifically targets the XBB.1.5 Omicron sub-variant and runs on the real-time PCR platforms LightCycler® 480...
AnPac Bio-Medical Science Announces Signing of US$5.2 Million of Definitive Investment Agreements
New York, NY, Jan. 25, 2023 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (the “Company”) (Nasdaq: ANPC), a biotechnology company...
Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor
– Dr. De Backer to assume CEO role on April 3, 2023 – – Upon his retirement as CEO, Dr....
Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
Recruitment ongoing in Europe, Asia-Pacific, and the U.S. for study of rapidly progressive Parkinsonian DisorderMELBOURNE, Australia AND SAN FRANCISCO, Jan. 25,...
Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients
~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in...
Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal
Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance...